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Brief Definit ive Report
Rheumatoid arthritis (RA) pathogenesis is 
characterized by a hyperplastic synovial mem-
brane caused by synovial cell proliferation and 
infiltration by inflammatory cells (Müller- 
Ladner et al., 2005). Synovial fibroblasts (SFs) 
are among the dominant cell types of the ar-
thritic synovium that under the influence of 
the inflammatory milieu and/or possible epi-
genetic changes become activated and hyper-
plastic, releasing several effector signals including 
proinflammatory factors and tissue-remodeling 
enzymes (Karouzakis et al., 2009).
Autotaxin (ATX) is a secreted lysophos-
pholipase D, widely present in biological fluids, 
catalyzing the conversion of lysophosphatidyl-
choline (LPC) to lysophosphatidic acid (LPA; 
Aoki, 2004; van Meeteren and Moolenaar, 
2007). LPA evokes growth factor–like responses 
in almost all cell types, including cell growth, 
survival, differentiation, and motility (Mills and 
Moolenaar, 2003). The wide variety of LPA 
effector functions is attributed to at least five 
G-protein–coupled LPA receptors (LPARs) 
with overlapping specificities and widespread 
distribution (Choi et al., 2008).
Increased ATX expression has been detected 
in a large variety of cancers (van Meeteren and 
Moolenaar, 2007); in this study, substantial ATX 
expression is detected from SFs in arthritic 
joints of animal models and human patients. 
Conditional genetic ablation of ATX in SFs 
(and other mesenchymal cells) is shown to 
attenuate disease pathogenesis, attributed to 
diminished LPA signaling to SFs.
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Rheumatoid arthritis is a destructive arthropathy characterized by chronic synovial inflam-
mation that imposes a substantial socioeconomic burden. Under the influence of the  
proinflammatory milieu, synovial fibroblasts (SFs), the main effector cells in disease patho-
genesis, become activated and hyperplastic, releasing proinflammatory factors and tissue-
remodeling enzymes. This study shows that activated arthritic SFs from human patients and 
animal models express significant quantities of autotaxin (ATX; ENPP2), a lysophospho-
lipase D that catalyzes the conversion of lysophosphatidylcholine to lysophosphatidic acid 
(LPA). ATX expression from SFs was induced by TNF, and LPA induced SF activation and 
effector functions in synergy with TNF. Conditional genetic ablation of ATX in mesen-
chymal cells, including SFs, resulted in disease attenuation in animal models of arthritis, 
establishing the ATX/LPA axis as a novel player in chronic inflammation and the pathogen-
esis of arthritis and a promising therapeutic target.
© 2012 Nikitopoulou et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). After 
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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(VCAM+) and subintimal (VCAM) SFs (Edwards, 2000) 
express ATX (Fig. 1 d). Moreover, TNF, the major proin-
flammatory cytokine that drives disease development in this 
animal model, was shown to induce ATX expression from 
WT SFs ex vivo, both at the mRNA (Fig. 1 e) and protein 
level (intracellular or secreted; Fig. 1, f and g, respectively), 
most likely through an NF-B–dependent mechanism 
(Zhao et al., 2008). Previous studies have also suggested 
modulation of ATX expression from other cytokines (Santos 
et al., 1996; Kehlen et al., 2001), although more detailed 
studies are needed.
To validate the results in vivo, immunostaining was used 
to assess ATX expression in the arthritic joints of three animal 
models of arthritis (Kollias et al., 2011): two inflammatory 
driven by TNF overexpression, the hTNF+/ transgenic 
(Keffer et al., 1991) and the TnfARE/+ knockin (Kontoyiannis 
et al., 1999), and one autoimmune, collagen-induced ar-
thritis (CIA; Campbell et al., 2000). In all models, substantial 
ATX expression was detected in the synovial tissue of in-
flamed joints compared with the almost complete absence of 
staining in WT control joints (Fig. 2, a and b). In accordance 
with the ex vivo results, ATX staining was localized in SFs, 
as shown with immunostaining for vimentin in se-
quential joint sections from hTNF+/ mice (Fig. 2 c 
and Fig. S1, a and d). Constitutive ATX expression 
was also noted in chondrocytes, in line with its sug-
gested role in mesenchymal development as a Bmp-2 
downstream target (Bächner et al., 1998); however, 
their relative contribution to the synovium ATX 
levels is negligible in comparison with the acti-
vated SFs in the hyperplastic synovial membrane. 
RESULTS AND DISCUSSION
Increased, TNF-driven ATX expression  
from SFs in mouse arthritic joints
Increased ATX messenger RNA (mRNA) expression has 
been previously detected through differential expression 
profiling in primary arthritic mouse SFs isolated from an 
animal model of inflammatory arthritis (Aidinis et al., 2005), 
confirmed here with quantitative RT-PCR (Q-RT-PCR; 
not depicted). No ATX mRNA expression was detected 
in primary immune cells even upon their activation (not 
depicted), an observation consistent with the expression of 
other ENPP family members in these cell types (Stefan et al., 
2005; van Meeteren and Moolenaar, 2007). Immunostain-
ing of ex vivo cultured primary SFs further confirmed the 
increased ATX expression in arthritic (hTNF+/) SFs 
(Fig. 1 a). Accordingly, ATX was also detected in SF super-
natants, where arthritic SFs were found to secrete signifi-
cantly more ATX than WT SFs (Fig. 1, b and c). The 
increased ATX expression in arthritic SFs was also con-
firmed by FACS analysis (not depicted), which further indi-
cated that the vast majority of ATX-expressing cultured 
cells were fibroblasts (vimentin+) and that both intimal 
Figure 1. Increased ATX expression in arthritic 
(hTNF+/) primary mouse SFs. (a) SFs from WT and  
hTNF+/ littermate mice were cultured and stained for ATX 
(red) and nuclei/DNA (DAPI; blue). +GB indicates cultures 
treated with Golgi block (Brefeldin A). Ctrl refers to negative 
control. Data are representative of three independent experi-
ments. Bars, 20 µm. (b) ATX protein levels in culture super-
natants from WT and hTNF+/ SFs were analyzed by Western 
blot. 4F1 refers to a rat monoclonal Ab against ATX; Caym. 
refers to a commercial (Cayman Chemical) polyclonal Ab. 
Data are representative of four independent experiments.  
(c) Densitometric analysis of b. (d) Expression of ATX, vimentin, 
and VCAM by arthritic SFs was analyzed by flow cytometry. 
Data are representative of three independent experiments. 
(e) ATX mRNA in mouse WT SFs cultured for 24 h in the ab-
sence (control) or presence of 10 ng/ml TNF was analyzed by 
Q-RT-PCR (n = 4). Data are representative of three indepen-
dent experiments. (c and e) Mean ± SE is shown. *, P < 0.05.  
(f and g) WT SFs were stimulated with the indicated concen-
trations of TNF, and cell extracts (f) or supernatants (g) were 
analyzed for ATX or tubulin expression by Western blot.  
Total protein in supernatants was quantified by the Bradford 
assay. Recombinant ATX (rATX) or native (nATX) was used  
as a positive control. Data are representative of two inde-
pendent experiments. Black lines indicate that intervening 
lanes have been spliced out.
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On the contrary, low constitutive expression from SFs in 
healthy tissue was noted and found dramatically increased 
in the arthritic joint (Fig. 2 d). Increased ATX protein 
levels were also detected in the plasma of arthritic (hTNF+/) 
mice using ELISA assays (Fig. 2 e). Arthritic mice presented 
with decreased levels of LPC, the substrate of ATX, as 
measured by liquid chromatography mass spectrometry 
(LC/MS; Fig. 2 f); however, as other phospholipid enzymes 
are also involved in LPC metabolism, the decrease in LPC 
levels cannot be attributed solely to ATX. No differences 
were detected in LPA levels in both plasma and joint tis-
sues (not depicted), most likely because of the rapid turn-
over of LPA (Albers et al., 2010) and the possible local 
delivery to its receptors by cell-bound ATX (Hausmann 
et al., 2011).
Anti-TNF treatment (biweekly intraperitoneal injections of 
10 mg/kg infliximab) of the inflammatory animal model 
(hTNF+/) attenuated ATX expression (Fig. S1, e and f), 
consistent with the in vitro results, suggesting that ATX 
induction in arthritic SFs is a downstream event of exacer-
bated TNF signaling in the synovium.
The increased ATX expression from arthritic SFs was 
also verified at the transcriptional level by crossing arthritic 
(hTNF+/) mice with the heterozygous complete KO 
mouse for ATX (Enpp2LacZ/+; Fig. 2 d), where the ATX 
promoter in one allele is driving LacZ expression instead 
of ATX (Koike et al., 2009). The results, in accordance with 
ATX immunostaining, indicate constitutive expression of 
ATX from chondrocytes in healthy tissue, exhibiting no ap-
preciable expression differences upon disease development. 
Figure 2. Increased ATX expression in mouse arthritic joints in vivo. (a) Representative immunohistochemistry images showing the expression of 
ATX in inflamed joints of three animal models of arthritis and respective WT littermate controls. Identical ATX staining was obtained in sequential sections 
(Fig. S1 a) and with different anti-ATX Abs (Fig. S1, b and c). (b) Quantification of ATX expression in mouse synovial tissues, as seen in a, was performed as 
described in Materials and methods (hTNF+/, n = 10; TnfARE/+ and CIA, n = 3). (c) Immunostaining of ATX (and its isotype control) or vimentin in sequen-
tial sections of mouse synovial tissues. (d) Representative whole mount X-gal staining (left) and X-gal staining on joint sections (right) from WT and 
hTNF+/ mice carrying one genetically modified allele driving LacZ expression under the control of the ATX promoter (n = 3). (e) Plasma levels of ATX in 
littermate pairs of WT and hTNF+/ mice at the time of sacrifice (n = 10; litters = 4). (f) Measurement of (total) LPC plasma levels with LC/MS in WT and 
hTNF+/ mice at the time of sacrifice (n = 9; litters = 2). (b, e, and f) Mean ± SE is shown. *, P < 0.05. Bars, 50 µm.
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RA patients, in agreement with a previous study suggesting a 
role for phospholipid homeostasis in RA (Fig. 3 h; Fuchs et al., 
2005). No significant differences in LPA levels were detected 
(not depicted). However, large cohort studies are required to 
establish ATX as a possible biomarker for RA and to examine 
phospholipid homeostasis in detail.
Conditional genetic ablation of ATX in mesenchymal  
cells attenuates disease development
To dissect the possible role of ATX in disease development, 
ATX expression was conditionally ablated using a conditional 
(LoxP) KO mouse for ATX (Enpp2n/n; Fotopoulou et al., 
2010) crossed with a transgenic mouse expressing the Cre re-
combinase under the control of the collagen VI (ColVI) pro-
moter, resulting in 80% recombination efficiency in SFs 
(Armaka et al., 2008). No apparent phenotype was observed 
in Enpp2/ColVICre+/ mice, which were healthy and fer-
tile, exhibiting no differences in systemic levels 
of ATX/LPA (not depicted) and normal joint 
architecture (Fig. 4 c).
Arthritic disease development upon con-
ditional deletion in SFs (and other mesenchymal 
cells) was first assessed in the inflammatory 
arthritis model (hTNF+/). The lack of ATX SF 
expression in the joints of Enpp2/ColVICre+/ 
hTNF+/ mice resulted in a striking decrease in 
inflammation and synovial hyperplasia, as indi-
cated by histopathological analysis of the joints 
(Fig. 4, a and b). PCR analysis of DNA ex-
tracted from the corresponding joint sections in-
dicated correct Enpp2 recombination (Fig. S2 a). 
Ablation efficiency was further evaluated by 
immunohistochemical staining (Fig. S2 b), and 
a direct correlation of ATX expression with 
histopathological score was observed (Fig. S2 c). 
No decrease of the minimal constitutive ATX 
Increased ATX expression from SFs of RA patients
Significant expression of ATX was also detected at the sub-
lining areas and sites of destruction in joints of RA patients 
(Fig. 3, a–c), localized at SFs, as shown with double labeling 
with the fibroblast-specific marker collagen prolyl 4-hydroxylase 
(P4H; Fig. 3 d; Petrow et al., 2000). Moreover, SFs isolated 
from RA patients were shown to express significantly more 
ATX mRNA than SFs isolated from osteoarthritis (OA) 
patients (Fig. 3 e). ATX staining was also observed in T cell 
follicles of the arthritic synovium (not depicted), in line with 
the suggested function of ATX as an adhesive substrate for 
migrating lymphocytes (Kanda et al., 2008).
Increased ATX levels were also detected in the serum and 
synovial fluid of human RA patients (Fig. 3, f and g, respec-
tively; no significant differences in age and sex distribution 
among groups). Consistent with results obtained from arthritic 
mice, decreased levels of LPC were found in the plasma of 
Figure 3. Increased ATX expression in RA patients. 
(a) Representative sections from RA and OA synovial 
tissues stained for ATX or isotype IgG control. (b) The 
expression of ATX from tissues shown in a was quantified 
as described in Materials and methods (n = 8). (c) ATX 
staining upon the addition of the immunogenic blocking 
peptide. (d) Representative double staining of human RA 
tissue section for ATX and P4H. (e) Real-time PCR analy-
sis of ATX expression in SFs isolated from subjects with 
OA or RA (n = 3). (f) Measurement of ATX levels in sera 
from RA and OA patients (n = 26). Personal and clinical 
patient information is included in Table S1. (g) Measure-
ment of synovial fluid ATX levels with ELISA from RA and 
OA patients (n = 16 and 9, respectively). (f and g) Values 
are expressed as medians, and statistical significance was 
assessed using the Mann-Whitney Rank Sum test.  
Asterisks indicate a statistically significant (*, P < 0.05) 
increase. (h) Measurement of (total) LPC plasma levels 
with LC/MS in RA patients and healthy controls (Ctrl; n = 5). 
(b, e, and h) Mean ± SE is shown. *, P < 0.05. Bars, 50 µm.
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mouse SFs were found to express all five major LPARs (not 
depicted), as has been previously shown for human SFs 
(Zhao et al., 2008). Addition of LPA, but not LPC (if ATX 
was not added to convert it to LPA), to primary cultures 
stimulated the proliferation of WT SFs in a dose-dependent 
manner (Fig. 5, a–c) but did not affect macrophages that 
also express all major LPARs (not depicted). On the con-
trary, LPC was able to stimulate the proliferation of arthritic 
SFs, most likely because of their increased production of 
active ATX (Fig. 5 b). LPA stimulation of SFs also resulted 
in their increased adhesion and migration (Fig. 5, d and e, 
respectively), accompanied by rearrangements of their 
actin cytoskeleton (Fig. 5 f), as well as in the production of 
MMP9 (matrix metalloproteinase 9; Q-RT-PCR; Fig. 5 g), 
all previously reported to be functional properties of arthritic 
SFs (Aidinis et al., 2005). In addition, multiplex Luminex 
bead assays showed that LPA stimulated the secretion of 
various proinflammatory cytokines from SFs (TNF, IL-6, 
KC, MIP-1a, and RANTES; Fig. 5 h) but not from bone 
marrow–derived macrophages, activated or not (not depicted). 
More importantly, LPA was shown to synergize with TNF 
(Fig. 5 i), as previously reported for PDGF and EGF in 
other cell types (Cerutis et al., 1997; Sakai et al., 1999), sug-
gesting that the ATX/LPA axis is important in regulating 
and/or amplifying growth factor responses. LPA responses 
were inhibited not only by an inhibitor of G-protein signal-
ing as expected (PTX; Fig. 5 j), but also by inhibitors of 
ERK (extracellular signal-regulated kinase), p38, JNK, and 
Rho kinase signaling (PD98059, SB203580, SP600125, and 
Y27632, respectively; Fig. 5 j). Therefore, LPA stimulates 
its G-protein–coupled receptors, leading to mitogen-activated 
protein kinase (GPCR/MAPK)–dependent activation of SFs 
and their effector functions, consistent with its reported 
functions in various fibroblasts in different tissues (Nochi 
et al., 2008).
In conclusion, this study suggests that the proinflam-
matory milieu during the pathogenesis of RA stimulates 
local, TNF-driven, SF-specific ATX 
expression in the synovium, leading to 
expression from articular chondrocytes was observed (not 
depicted), ruling out a direct involvement of ATX expres-
sion from this cell type in disease development.
To examine whether deletion of ATX in cells other 
than SFs could indirectly affect disease development by 
possibly modulating systemic plasma ATX levels, it was 
next investigated whether systemic fluctuations of ATX 
and LPA plasma levels are able to alter disease develop-
ment. The arthritic hTNF+/ transgenic mice were mated 
with homozygous transgenic mice overexpressing ATX in 
the liver, driven by the human 1-antitrypsin inhibitor 
(a1t1) promoter (200% of normal plasma ATX and LPA 
levels; Pamuklar et al., 2009), as well as with the complete 
heterozygous KO mouse for ATX (50% of normal plasma 
ATX and LPA levels; Fotopoulou et al., 2010). No differ-
ences in the severity of arthritis were observed in this 
(hTNF+/) animal model (Fig. S3), highlighting the patho-
logical role of the local, SF-specific ATX expression in dis-
ease development.
To confirm the role of ATX in disease development in an 
inducible, autoimmune model, the effect of SF-specific ATX 
genetic ablation in the development of CIA (Campbell et al., 
2000) was next investigated. As expected for the C57BL/6 
genetic background (Campbell et al., 2000), 50% of WT 
Enpp2+/+ColVICre+/ mice developed disease symptoms, 
whereas the Enpp2/ColVICre+/ littermate mice were 
found protected from disease development (Fig. S2, d and e). 
Histopathological analysis of joints (Fig. 4, c and d; and 
Fig. S2, f–h) revealed a lack of synovial inflammation upon 
ATX ablation in SFs, thus confirming the significant role of 
ATX in disease pathogenesis.
ATX stimulates SF activation and effector  
functions through LPA signaling
To dissect the mechanistic implications of increased ATX 
expression in synovial inflammation and arthritis pathogen-
esis, a series of in vitro experiments were performed. Primary 
Figure 4. Genetic ablation of ATX from 
mesenchymal cells attenuates disease  
development. (a) Representative H&E-
stained sections of ankle joints from hTNF+/ 
mice with (Enpp2/ColVICre+/) or without 
(Enpp2+/+ColVICre+/) genetic deletion of ATX 
from SFs. (b) Quantification of disease severity 
in Enpp2/ColVICre+/hTNF+/ and Enpp2+/+ 
ColVICre+/hTNF+/ mice (n = 7; litters = 2). 
(c) Representative H&E-stained joint sections 
of Enpp2/ColVICre+/ and Enpp2+/+ 
ColVICre+/ mice upon CIA induction.  
(d) Quantitative assessment of synovial inflam-
mation in Enpp2/ColVICre+/ and Enpp2+/+ 
ColVICre+/ mice (n = 7; litters = 2). (b and d) 
Mean ± SE is shown. *, P < 0.05. Bars, 50 µm.
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MATERIALS AND METHODS
Animals. All mice were bred at the animal facilities of the Alexander Flem-
ing Biomedical Sciences Research Center (BSRC) under specific pathogen–
free conditions. Mice were housed at a temperature of 20–22°C, 55 ± 5% 
humidity, and a 12-h light–dark cycle; water and food were given ad libi-
tum. Mice were bred and maintained in their respective genetic backgrounds 
for >10 generations. All experiments were approved by the Institutional 
Animal Ethic Committee of BSRC Fleming (#232), as well as by the Veter-
inary Service and Fishery Department of the local government agency. 
the hydrolysis of circulating LPC and the local production 
of LPA. In turn, LPA activates SFs and their effector func-
tions and amplifies and/or regulates pathogenetic responses 
in synergy with TNF. Genetic deletion of ATX from SFs re-
sulted in disease attenuation in animal models of arthritis, 
thus establishing ATX as a novel player in chronic inflam-
mation and the pathogenesis of arthritis and a promising 
therapeutic target.
Figure 5. ATX stimulates SF activation and effector functions through LPA signaling. (a) Mouse WT SFs were stimulated for 24 h with the indi-
cated concentrations of LPA, and proliferation was measured with a [3H]thymidine uptake assay. Data are representative of eight independent experi-
ments. All values were normalized and compared with control values. (b) Mouse WT and hTNF+/ SFs were stimulated for 24 h with 10 µM LPA, 10 µM 
LPC, or 10 µM LPC together with 4 nM ATX, and proliferation was measured as in a (n = 3). Data are representative of three independent experiments.  
(c) LPA levels in culture supernatants from b. (d) SFs were plated in fibronectin-coated wells in the presence or absence of 10 µM LPA, and their adhesion 
was measured as described in Materials and methods. Data are representative of three independent experiments. (e) SFs were plated on Boyden chambers 
and were allowed to migrate under the influence of LPA for 4 h. Data are representative of three experiments. (f) SFs were treated for 4 h at 37°C with  
10 µM LPA, and F-actin was stained with TRITC–conjugated phalloidin. Data are representative of five independent experiments. Bars, 20 µm. (g) Mouse WT 
and hTNF+/ SFs were cultured for 4 h in the presence or absence of 10 µM LPA, and MMP9 mRNA was assessed with Q-RT–PCR. Results were normalized 
to the expression of b2m. Data are representative of three independent experiments. (h) Proinflammatory cytokine levels measured by ELISA in culture 
supernatants from mouse WT or hTNF+/ SFs, stimulated or not for 4 h with 10 µM LPA. Values were expressed as ratios over control (WT SFs). Data are 
representative of three independent experiments. (i) Mouse WT SFs were stimulated for 24 h with the indicated concentrations of LPA and/or TNF, and 
proliferation was measured as in a. All values were normalized to control values. The asterisks indicate a statistically significant (*, P < 0.001) increase of 
the combined TNF/LPA treatment as compared with individual treatments. Differences between all experimental group values were also statistically sig-
nificant compared with control. Data are representative of three experiments. Mean ± SE is shown. (j) Mouse WT and hTNF+/ SFs were treated with  
10 µM LPA, a G-protein inhibitor (50 ng/ml PTX), a Rho kinase inhibitor (10 µM Y27632), or JNK, ERK, and p38 inhibitors (10 µM SP600125, 10 µM PD98059,  
and 5 µM SB203580, respectively), and proliferation was measured as in a. Data are representative of three independent experiments. (a–e, g, h, and j) 
Mean ± SE is shown. *, P < 0.05.
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was blocked by incubation in 1% H2O2 for 10 min. Sections were then 
blocked with 2% BSA for 30 min and incubated overnight at 4°C with an 
anti-ATX Ab (from Phoenix Pharmaceuticals unless otherwise indicated) or 
an IgG rabbit isotype control. Washing in PBS-T was followed by incuba-
tion with HRP-conjugated anti–rabbit IgG for 30 min at room temperature. 
Bound peroxidase activity was detected by staining with DAB. Sections 
were counterstained with hematoxylin, mounted, and photographed under 
an ECLIPSE E800 microscope (Nikon) using the ACT-I software. Expres-
sion levels were quantified by using a three-point scale semiquantitative 
intensity score: 0 = no staining, 1 = weak expression, 2 = moderate expres-
sion, and 3 = strong expression.
Formalin-fixed, paraffin-embedded sections of RA and OA synovial 
tissue slides were deparaffinized and treated at 80°C for 30 min with citrate 
buffer, pH 6.0. After washing with H2O, the endogenous peroxidase was 
blocked with 1% H2O2 for 10 min. The slides were blocked with 2% goat 
serum for 1 h and incubated overnight at 4°C with a rabbit polyclonal Ab 
against ATX (Cayman Chemical) or IgG1 rabbit isotype control (Dako). 
After washing twice in PBS, the slides were incubated with their respective 
biotinylated secondary Abs for 30 min. The signal was amplified with HRP 
conjugated with streptavidin Vectastain Elite ABC kit (Vector Laboratories). 
The slides were then developed with a chromogenic substrate for peroxidase 
and counterstained with hematoxylin. ATX expression was quantified semi-
quantitatively, blindly by three different reviewers, on a five-point scale: 0 = no 
staining; 1 = weak expression, single cells stained; 2 = mild expression, lim-
ited areas stained; 3 = moderate expression, weak overall expression; and 4 = 
strong expression, strong overall staining.
LacZ staining. Joints were harvested as a block, and a paramedical patella 
incision was made on the joint to expose the inside. Harvested joints were 
fixed in formaldehyde/glutaraldehyde for 1 h at room temperature, washed 
three times in PBS/2 mM MgCl2, and incubated with 1 mg/ml 5-bromo-a-
chloro-3-inodyl--d-galactopyranoside (X-gal) in 0.1 M Na phosphate 
buffer, pH 7.3 (2 mM MgCl2, 0.01% Na deoxycholate, 0.02% NP-40, 5 mM 
K3Fe(CN)6, and 5 mM K4Fe(CN)6) at 37°C in the dark overnight. Tissues 
were rinsed three times in PBS/2 mM MgCl2 at room temperature and were 
then placed in decalcification buffer at 4°C for 6 d. After that, they were 
washed with PBS and embedded in paraffin. The resulting 4-µm sections 
were counterstained with eosin and visualized under an ECLIPSE E800 micro-
scope as in the previous section.
Cell isolation and culture. Primary SFs were isolated by enzymatic treat-
ment of the joints of 6-wk-old mice as previously described (Aidinis et al., 
2005). Cells from two to three mice were pooled and cultured in standard 
conditions: DME supplemented with 10% FBS and 1% penicillin-streptomycin, 
37°C, and 5% CO2 (Aidinis et al., 2005); all experiments were performed 
after two to three passages with 70–80% confluent cells and confirmed with 
independent isolations. All in vitro experiments were performed after over-
night serum starvation (supplemented with 0.2% fatty acid–free BSA). Cells 
were pretreated with the indicated concentrations of PTX and inhibitors of 
ERK, p38, JNK, and Rho kinase for 3 h before LPA stimulation. Brefeldin A 
(GolgiPlug; BD) was added to SF cultures for 4 h according to manufacturer’s 
instructions to prevent Golgi transport.
Flow cytometry. Cells were initially stained extracellularly with VCAM-1 
(CD106) and subsequently with a secondary (PE) conjugated Ab. For intra-
cellular stainings, cells were fixed and permeabilized with Cytofix/Cytoperm 
solution, followed by incubation with anti-ATX (1:200; Cayman Chemical) 
and antivimentin (1:50) Abs for 30 min. Primary Abs were detected after 
a 30-min incubation with anti–rabbit biotin Abs followed by PE-Cy5- 
streptavidin or with FITC-conjugated secondary Ab (all diluted 1:500). 
Analysis was performed using FACSCanto II and Diva software (BD).
Proliferation assay. SFs were grown in 24-well tissue-culture plates in 
DME. Preconfluent cell cultures were starved overnight, incubated for 24 h 
with LPA and the various compounds, and finally exposed to 0.5 µCi/ml 
The generation and genotyping instructions of Tg197 (hTNF+/; Keffer 
et al., 1991), TnfARE (Kontoyiannis et al., 1999), ColVI-Cre (Armaka 
et al., 2008), Enpp2LacZ/n (Koike et al., 2009), Enpp2n/n (Fotopoulou et al., 
2010), and Tg(a1t1)ATX+/+ (Pamuklar et al., 2009) mice have been previ-
ously described.
Animal models of arthritis. Both inducible and spontaneous animal 
models of arthritis were used in this study (Kollias et al., 2011). CIA was in-
duced in C57BL/6 mice as previously described (Campbell et al., 2000). In 
brief, mice were immunized with chicken collagen type II, followed by a 
boost immunization at day 21. Disease onset was observed at day 28; all 
experimental mice were sacrificed at day 60 after immunization. Tg197 
(hTNF+/) is a humanized TNF transgenic mouse with human TNF over-
expression resulting in the spontaneous development of chronic, erosive, 
and symmetrical polyarthritis (Kollias et al., 2011). Disease symptoms were 
observed 3 wk after birth; all experimental mice were sacrificed 5–6 wk after 
birth. TnfARE is a mouse mutant carrying a deletion of the ARE (AU-rich 
elements), 3 untranslated region regulatory element of TNF that results in 
loss of its posttranscriptional regulation. Deregulated TNF expression leads 
to the gradual development of spontaneous inflammatory polyarthritis and 
inflammatory bowel disease (Kontoyiannis et al., 1999).
Patients. Human synovial tissues and SFs were obtained at the time of joint 
replacement surgery at the Schulthess Clinic (Zurich, Switzerland). Sera 
from patients were obtained from the Schulthess Clinic. All patients, classi-
fied according to the 1987 criteria of the American College of Rheumatol-
ogy, signed an informed consent form where they agreed to the anonymous 
use of their samples for research purposes after approval of the Kantonale 
Ethikkommission, Spezialisierte Unterkommission für Spezialfächer (#475). 
All personal and clinical data of patients are included in Tables S1 and S2.
Reagents. 1-oleoyl-LPA (18:1) and 1-oleoyl-LPC (18:1) were purchased 
from Avanti Polar Lipids, Inc. ERK inhibitor PD98059, p38 MAPK inhibitor 
SB202190, and JNK inhibitor SP600125 were obtained from EMD. Fatty 
acid–free BSA, choline oxidase, peroxidase, TMB (3,3,5,5-tetramethylbenzi-
dine) substrate, phalloidin, and DAB (3,3-diaminobenzidine) were obtained 
from Sigma-Aldrich. Recombinant ATX and mouse TNF were purchased 
from R&D Systems. Native ATX refers to the 10× concentrated super-
natants of MDA-MB-43S cells (American Type Culture Collection), which 
are highly enriched in ATX. Fibronectin and Cytofix/Cytoperm solution 
were obtained from BD. Rabbit anti-ATX polyclonal antibodies (Abs) were 
purchased from Phoenix Pharmaceuticals and/or Cayman Chemical; rat 
monoclonal Abs (clone 4F1) against ATX were a gift from J. Aoki (Tohoku 
University, Aoba-ku, Sendai, Miyagi, Japan). Antivimentin Abs were pur-
chased from Millipore, and collagen P4H Abs were purchased from Acris. 
Secondary Alexa Fluor 555–conjugated anti–rabbit Ab was obtained from 
Invitrogen; all secondary horseradish peroxidase (HRP)–conjugated Abs and 
isotype controls were obtained from and SouthernBiotech.
Histopathology and arthritic score. Paraffin-embedded mouse joint tis-
sue samples were sectioned and stained with hematoxylin and eosin (H&E) 
as previously described (Aidinis et al., 2005; Armaka et al., 2008). Arthritic 
histopathology in mice was assessed (in a blinded fashion from three inde-
pendent reviewers) using a semiquantitative scoring system as previously de-
scribed for CIA (0 = no detectable pathology; 1 = mild arthritis, minimal 
synovitis and cartilage loss; 2 = moderate arthritis, synovitis and bone ero-
sions; and 3 = severe arthritis, synovitis, extensive erosions, and disrupted 
joint architecture; Campbell et al., 2000). The scoring system for Tg197 
(hTNF+/) is as follows: 0 = no detectable pathology, 1 = synovial mem-
brane hyperplasia, 2 = pannus and fibrous tissue formation and focal bone 
erosion, 3 =cartilage destruction and bone erosion, and 4 = extensive carti-
lage destruction and bone erosion.
Immunohistochemistry. Paraffin-embedded mouse joint tissue samples 
(4-µm-thick sections) were deparaffinized, and endogenous peroxidase activity 
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Primer sequences (designated as s, sense; and as, antisense) and product sizes were 
as follows: Enpp2 (s, 5-GTGAAATATTCTTAATGCCTCTCTG-3; 
as, 5-GCCTTCCACATACTGTTTAATTCC-3; 410 bp), b2m (s, 5-TTC-
TGGTGCTTGTCTCACTGA-3; as, 5-CAGTATGTTCGGCTTCCC-
ATTC-3; 104 bp), MMP-9 (s, 5-CAGATGATGGGAGAGAAGCA-3; 
as, 5-CGGCAAGTCTTCAGAGTAGT-3; 222 bp), LPA1 (s, 5-GAG-
GAATCGGGACA-3; as, 5-TGAAGGTGGCGCTC-3; 227 bp), LPA2 
(s, 5-GACCACACTCAGCCTAGTCAAGAC-3; as, 5-CAGCATCTC-
GGCAGGAAT-3; 200 bp), LPA3 (s, 5-GCTCCCATGAAGCTAAT-
GAAGACA-3; as, 5-TACGAGTAGATGATGGGG-3; 188 bp), LPA4 
(s, 5-AGTGCCTCCCTGTTTGTCTTC-3; as, 5-GCCAGTGGC-
GATTAAAGTTGTAA-3; 142 bp), and LPA5 (s, 5-ACCCTGGAGGT-
GAAAGTC-3; as, 5-GACCACCATATGCAAACG-3; 176 bp).
Statistical analysis. Unless otherwise indicated, statistical significance was 
assessed in pairwise comparisons with control values by using a paired Student’s 
t test, after confirmation of normal distributions with SigmaPlot 11.0 (Systat 
Software). Unless otherwise indicated, all values are expressed as means ± 
SE, and p-values <0.05 were considered significant (*).
Online supplemental material. Fig. S1 contains various controls support-
ing an increased ATX expression in arthritic joints, as well as supporting that 
TNF treatment of the transgenic animal model of arthritis attenuates ATX 
expression. Fig. S2 contains various controls on the effects of the conditional 
ATX deletion in modeled disease development. Fig. S3 shows that systemic 
fluctuations of ATX serum levels do not affect disease development in the 
hTNF+/ animal model. Tables S1 and S2 contain personal and clinical data 
of patients used for determination of ATX levels in sera and synovial fluids, 
respectively. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20112012/DC1.
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 Figure S1.  Increased, TNF-driven ATX expression in mouse arthritic joints in vivo. (a) Representative staining for ATX (Phoenix Pharmaceuticals) 
and vimentin in adjacent sections of mouse arthritic joints. (b) Validation of ATX immunostaining in mouse arthritic joint sections using a different anti-
ATX Ab (Cayman Chemical) in serial dilutions. (c) ATX immunostaining in joint sections from  hTNF +/   mice using a monoclonal Ab (4F1) and its isotype 
control. (d) Vimentin immunohistochemistry in joint sections from  hTNF +/   mice and respective isotype control. (e) ATX immunostaining in joint sections 
from  hTNF +/   mice treated with infl iximab or vehicle. (f) Quantifi cation of ATX expression in joints from  hTNF +/   mice treated with infl iximab or vehicle. 
Expression levels were quantifi ed as described in Materials and methods. Mean ± SE is shown. *, P < 0.05. Bars, 50 μm. 
ATX participates in the pathogenesis of arthritis | Nikitopoulou et al. S2
 Figure S2.  Genetic ablation of ATX from mesenchymal cells attenuates disease development. (a) PCR analysis of whole joint DNA extracted from 
paraffi n block sections of the indicated mouse genetic strains confi rmed correct  Enpp2 recombination. (b) Immunostaining of ATX in arthritic mouse 
joints of the indicated genotypes showing effi cient recombination. (c) ATX expression in joint sections from  hTNF +/   mice was quantifi ed, as described in 
Materials and methods, and was correlated with the equivalent histopathological score. (d) Incidence of arthritis (shown as cumulative percentage) in 
 Enpp2 +/+ ColVICre +/   and  Enpp2   /   ColVICre +/   mice, relative to time, after primary immunization with CII. (e) Mean clinical scores (±SEM) of the indicated 
mice relative to time after primary immunization with CII. Statistical signifi cances were assessed using a Mann-Whitney Rank Sum test. (f) PCR analysis 
of  Enpp2 recombination as in a. (g) Immunohistochemistry for ATX in joint sections from the indicated mice, showing effi cient recombination. (h) Scatter 
plot showing the correlation of mouse histopathological score with ATX expression as in c. Bars, 50 μm. 
 Figure S3.  Systemic fl uctuations of ATX do not affect arthritic disease development in the  hTNF +/   animal model. (a) Representative H&E 
joint sections of  hTNF +/   arthritic mice, carrying an ATX transgene driven by the  a1t1 promoter (in homozygosity, Tg ATX +/+ ; or heterozygosity, Tg ATX +/   ). 
(b) Representative H&E joint sections from  hTNF +/   mice after crossing with the complete heterozygous KO mouse for ATX ( Enpp2 +/   ). (c) Quantitative 
assessment of disease severity in all the groups of mice shown in a and b. Data are expressed as the mean ± SD ( n = 5–10). Bars, 50 μm. 
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 Table S1. Personal and clinical data of patients used for determination of ATX levels, showing a statistically signifi cant increase 
of ATX in RA sera 
Sample no. Age Gender Diagnosis DAS28 RF CRP Anti-CCP Medication ATX
 yr  IE/ml  mg/l  E/ml  ng/ml 
S5661 51 F RA 5.7 79 4 210 Humira 1,035.26
S5640 57 F RA 2.3 <8 <1 390 Rituximab 221.58
S5859 56 F RA 5.5 194 11 7,429 Humira 1,317.72
S5564 57 F RA 2.8 21 3 802 - 440.00
S5711 55 F RA 4.9 - <1 2,680 Humira 439.30
S5509 56 M RA 3.7 186 4 730 Rituximab 684.04
S5620 58 M RA 4.6 398 41 1,499 Abatacept 252.46
S5451 60 M RA 4.9 <10 12 348 Rituximab 237.72
S5166 57 M RA 5.2 286 15 1,263 Rituximab 1,856.49
S5749 51 M RA 4.6 143 7 5,418 Humira 962.28
S4040 57 M RA - <10 78 2 - 207.89
S4104 53 M RA - - - 1,162 - 727.54
S4120 58 M RA - - <2 - - 550.53
S3980 50 F RA - <10 11 21 - 314.56
S4006 53 F RA - - - 90 - 448.77
S4002 54 F RA 4.1 50 5 200 - 322.81
S4021 58 F RA - - 2 - - 905.44
S4099 54 F RA - - 93 - - 1,718.95
S4121 58 F RA - - 16 35 Remicade 2,454.04
S5018 56 F RA 4.5 271 10 180 Humira 3,498.42
S5044 60 F RA - 92 193 1,845 Humira 237.37
S5220 50 F RA 4.2 <10 1 1 Rituximab 311.40
S 5661 51 F RA 5.7 79 4 210 Humira 893.16
S 5605 56 M RA 3.8 142 8 566 Rituximab 474.91
S 6004 62 M RA 5.2 1,850 20 1,616 Tocilizumab 2,783.33
S4110 55 F RA 5.9 - - - - 3,290.35
S3316 58 M OA - - - - - 151.93
S3318 58 M OA - - - - - 182.98
S3357 57 M OA - - - - - 200.53
S3362 57 F OA - - - - - 170.88
S3409 60 F OA - - - - - 447.54
S3411 53 F OA - - - - - 157.89
S3414 54 M OA - - - - - 130.35
S3413 56 F OA - - - - - 117.37
S3416 57 M OA - - - - - 176.49
S3419 51 F OA - - - - - 511.40
S3249 50 F OA - - - - - 566.84
S3353 53 F OA - - - - - 268.07
S3400 50 F OA - - - - - 235.79
S3419 52 F OA - - - - - 105.79
S3468 53 F OA - - - - - 384.74
S3562 54 F OA - - - - - 234.56
S3643 56 F OA - - - - - 366.84
S3580 58 F OA - - - - - 788.95
S3334 54 M OA - - - - - 717.19
S3641 54 M OA - - - - - 246.84
S3533 52 M OA - - - - - 232.81
S3521 59 M OA - - - - - 573.86
S3485 59 M OA - - - - - 255.44
OAS004 63 F OA - - 1.5 - - 203.68
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 Table S1. Personal and clinical data of patients used for determination of ATX levels, showing a statistically signifi cant increase 
of ATX in RA sera (Continued) 
Sample no. Age Gender Diagnosis DAS28 RF CRP Anti-CCP Medication ATX
OAS015 57 M OA - - 10 - - 121.23
OAS016 65 F OA - - 0.8 - - 239.12
 As shown in  Fig. 3 f . DAS28, RF, CRP, and anti-CCP were estimated at the same date (±2 d). “–“ denotes unavailable data. 
 Table S2. Personal and clinical data of patients used for determination of ATX levels, showing a statistically signifi cant increase 
of ATX in RA synovial fl uids 
Sample no. Age Gender Diagnosis DAS28 RF CRP Anti-CCP Medication ATX
 yr  U/ml  mg/l  E/ml  ng/ml 
SF676 57 M RA - 2,140 58 - - 6,645.97
SF624 40 F RA - - 14 - - 8,396.42
SF669 41 F RA - 22 4 - - 5,866.27
SF657 48 F RA 7.8 - <2 - - 7,057.91
SF675 65 M RA - 81 3 - - 6,900.30
SF673 45 F RA 6.5 332 131 - - 7,608.36
SF729 58 F RA - - - - - 7,882.99
SF692 72 M RA - - 3 - - 5,672.84
SF712 55 F RA - - 12 - Remicade 6,240.00
SF793 35 F RA 7.5 192 7 - Humira 5,826.87
SF757 47 M RA - <10 <2 1 Remicade 6,690.15
SF746 46 F RA 6.5 240 54 - - 12,255.52
SF743 45 F RA - <10 63 2 Remicade 5,909.25
SF771 71 F RA 5.7 - 56 - - 10,060.90
SF765 59 M RA 7 - - - - 5,799.40
SF794 50 F RA 7.6 92 193 1,845 Humira 5,619.10
SF588 57 F OA - - - - - 4,746.27
SF792 60 F OA - - - - - 5,374.33
SF795 77 F OA - - - - - 6,567.16
SF803 71 F OA - - - - - 4,234.03
SF807 74 M OA - - - - - 5,732.54
SF596 72 F OA - - - - - 6,241.19
SF648 53 F OA - - - - - 6,107.46
SF805 65 F OA - - - - - 4,808.36
SF806 80 F OA - - - - - 5,612.40
As shown in  Fig. 3 g . DAS28, RF, CRP, and anti-CCP were estimated at the same date (±2 d). “–“ denotes unavailable data.
